Method for inducing satellite glial cells to be inversely differentiated into neural stem cell-like cells and application
By constructing the expression vector that knocks down Sox9 and improving medium conditions, satellite glial cells were successfully induced to reverse differentiate into neural stem cell-like cells, solving the problems of low induction of anti-differentiation efficiency and tumorigenic risk in the prior art, and realizing cells efficient differentiation and neural function recovery.
Patent Information
- Application Number
- CN202411578204.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-07
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art has not yet effectively induce the reverse differentiation of satellite glial cells into neural stem cell-like cells, and the lentiviral vectors have a risk of tumorigenicity, and there is a lack of efficient direct lineage reprogramming technology.
By constructing a expression vector that knocked down Sox9, transfected dorsal root ganglion satellite glial cells using lentiviral packaging, combined with improved DMEM/F12 medium and FBS induction medium, the satellite glial cells were successfully induced to reverse differentiate into neural stem cell-like and their active state was identified by immunofluorescence and flow.
It has achieved efficient reverse differentiation of satellite glial cells into neural stem cell-like cells, which has strong proliferation ability and has the potential for directional differentiation. It has significantly alleviated the release of inflammatory factors in the mouse sciatic nerve injury model, and promoted the expression of neurotrophic factors and nerve growth factors. , improve motor and neurological recovery.
Smart Images

Figure CN119082031A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of cell reverse differentiation, and in particular to a method for inducing satellite glial cells to reversely differentiate into neural stem cell-like cells and application thereof. Background Art
[0002] Dorsal root ganglia (DRG) are located near the dorsal horn of the spinal cord and contain the cell bodies of primary afferent neurons that transmit pain signals from the peripheral area to the central nervous system. Sensory neurons cannot form proper synapses at the DRG, but the somata of the neurons are able to release neurotransmitters such as glutamate, ATP, and substance P, and also express multiple receptors for neurotransmitters and inflammatory mediators. In the DRG, neuronal cell bodies are surrounded by satellite glial cells (SGC). These glial cells play an active role in regulating physiological pain activities. When neuroinflammation occurs, SGCs undergo activated morphological changes. SGCs not only support, protect, and nourish neurons, but also have diversity and can express markers of different cells.
[0003] Cell reprogramming refers to the conversion of one cell type into another by changing its epigenetic marks. This can be achieved by three different methods: somatic cell nuclear transfer, cell fusion, and transcription factor (TF)-mediated reprogramming. TF-mediated reprogramming can be performed in a variety of ways, by direct transdifferentiation into a new cell type (bypassing the intermediate pluripotent stage), by returning to a pluripotent state before redifferentiating into a new cell type (also known as induced pluripotency), or by using an induced pluripotent pathway without reaching a pluripotent state. Transcription factor combinatorial screening is commonly used in the study of cell reprogramming. In nervous system research, glial cells have a high level of plasticity, and many types of these cells are present in the nervous system. Glial cells provide a variety of therapeutic targets for nervous system diseases and injury repair. Cell reprogramming technology provides an effective way for cell conversion during neural regeneration, and transcription factor-mediated reprogramming can promote the understanding of how glial cells mature into functional neurons and promote neural function recovery. Studies have shown that reprogramming astrocytes using retroviral transcription factors carrying ASCL1 or NEUROG2 can convert them into fully functional neurons in vitro. In addition, co-expression of SOX2 and ASCL1 can induce astrocytes isolated from the brain of adult mice to transform into neurons. The reprogramming of satellite glial cells induced by SOX10 into oligodendrocytes is also related to many transcription factors, such as NKx2.2 and MYRF. Direct lineage reprogramming technology greatly reduces the tumorigenicity of induced pluripotent stem cell redifferentiation. Related experimental results confirm that the initial cells or transformed cells transplanted into animals during direct lineage reprogramming rarely cause tumors. However, the existing direct lineage reprogramming technology still uses lentiviral vectors to overexpress related genes. Due to the characteristics of lentivirus inactivating key tumorigenic genes and gene recombination, there is still the possibility of tumorigenesis. At present, there is no literature reporting the reverse differentiation of satellite glial cells into neural stem cell-like cells. Summary of the invention
[0004] The invention provides a method for inducing satellite glial cells to reversely differentiate into neural stem cell-like cells, which has high reverse differentiation efficiency, strong proliferation ability of the induced cells and directional differentiation potential.
[0005] In order to solve the above technical problems, the technical scheme of the present invention is as follows: a method for inducing satellite glial cells to reversely differentiate into neural stem cell-like cells, taking dorsal root ganglia after sciatic nerve injury and placing them in primary culture medium for culture to obtain dorsal root ganglion satellite glial cells, using lentivirus to package the constructed Sox9 knockdown expression vector and then transfect the dorsal root ganglion satellite glial cells, and using DMEM / F12 culture medium containing puromycin to screen dorsal root ganglion satellite glial cells with stable expression; then using improved DMEM / F12 culture medium and FBS induction culture medium to successively culture dorsal root ganglion satellite glial cells to obtain neural stem cell-like cells; The process of constructing a shRNA expression vector for knocking down Sox9 is as follows: inserting the shRNA sequence into the plasmid, and then transfecting the expression vector into cells, wherein the target sequence of the shRNA is shown in SEQ ID NO.1, and the sequence of the expression vector is shown in SEQ ID NO.5; the expression vector is packaged by lentivirus.
[0006] As a further description of the above scheme: the construction process of the expression vector for knocking down Sox9 is as follows: The plasmid and Sox9 interference fragment were double-digested with EcoR I and Age I restriction endonucleases, and the linear plasmid was recovered after electrophoresis; the Sox9 CDS sequence was amplified by PCR, and the obtained double-stranded DNA was digested to obtain the shRNA Oligo fragment, and the shRNA fragment was connected with the plasmid to obtain pLV[shRNA]-EGFP / Puro-U6>mSox9[shRNA]; Add pLV[shRNA]-EGFP / Puro-U6>mSox9[shRNA] to competent cells, flick the tube wall several times to mix, place on ice for 20-40 minutes, heat shock at 41-43℃ for 80-100 seconds, incubate in ice water bath for 1.5-2.5 minutes, add LB medium, place on a 37℃ shaker for 0.8-1.2 hours; take the bacterial solution and evenly spread it in DMEM / F12 medium containing 0.09-0.11 mg / mL ampicillin, and invert and culture in a constant temperature incubator for 12-16 hours; when colonies grow on the plate, pick an appropriate amount of colonies and place them in a medium containing 90-110 mg·L -1 In LB medium containing ampicillin, shake at 36.8-37.2℃ overnight, and take an appropriate amount of bacterial solution for PCR and agarose gel electrophoresis identification; The identified positive clone transformants were inoculated into an appropriate amount of 90-110 mg·L -1 The cells were cultured in ampicillin-containing LB liquid medium at 36.8-37.2°C for 12-16 hours, and an appropriate amount of bacterial solution was taken for sequencing. The plasmids of the positive bacteria with successful sequencing were extracted using a plasmid extraction kit, and then lentiviral packaging was performed.
[0007] Preferably, the improved DMEM / F12 medium is a DMEM / F12 medium with 1.5-2.5% (V / V) B27 and 1.5-2.5% (V / V) penicillin-streptomycin solution added. B27 has immunomodulatory and nutritional effects on neural cells and stem cells, and penicillin-streptomycin as a double antibody can help cells resist contamination. Primary cell transfection is particularly prone to contamination, and the reagents are toxic, which can easily cause cell death and low transfection efficiency, so anti-pollution and cell nutrition must be performed simultaneously.
[0008] Preferably, the composition of the FBS induction medium is as follows: 0.5-5 mL of FBS is added to 50 mL of improved DMEM / F12 medium. FBS induction medium is a DMEM / F12 medium with different proportions of FBS added. FBS has the ability to promote stem cell redifferentiation. The FBS induction medium is used to detect whether the satellite glial reversely differentiated neural stem cell-like cells have the ability to redifferentiate, which once again proves that the satellite glial has indeed reversely differentiated.
[0009] The present invention also provides neural stem cell-like cells obtained by the method of inducing satellite glial cells to reversely differentiate into neural stem cell-like cells.
[0010] The present invention also provides application of the neural stem cell-like cells in preparing a medicine for repairing sciatic nerve damage.
[0011] The characteristics of the present invention are as follows: The present invention provides a method for inducing satellite glial cells to reversely differentiate into neural stem cell-like cells. After establishing a sciatic nerve injury model, satellite glial cells are taken out, and stable primary satellite glial cells with knockdown of the key transcription factor Sox9 for glial generation are constructed. Cell morphology is observed by white light inverted microscope and transmission electron microscope, and the expression of neural stem cell markers Nestin and SOX2 is detected by immunofluorescence, and its activity state is identified by flow cytometry. The induced cells are cultured with different volume fractions of fetal bovine serum (FBS) to direct differentiation into glial cells and neurons. The present invention successfully uses the transcription factor Sox9 to induce primary satellite glial cells after sciatic nerve injury into neural stem cell-like cells. In this process, the present invention finds that DRG-SGCs may be transformed into "reactive DRG-SGCs" to respond to injury after injury, and knocking down Sox9 cooperates with it to promote reverse differentiation of injury-responsive DRG-SGCs. The induced cells meet the characteristics of neural stem cells: strong proliferation ability and directional differentiation potential, which provides reference value for further research on peripheral nervous system regeneration.
[0012] After obtaining dorsal root ganglion neural stem cell-like cells, the present invention established a mouse sciatic nerve injury model, observed the proliferation ability of allogeneic homologous dorsal root ganglion stem cell-like cells entering the injury site by BrdU labeling, and directly injected the optimal number of allogeneic homologous dorsal root ganglion stem cells into the sciatic nerve injury site. The experimental results show that the neural stem cell-like cells can reduce the release of inflammatory factors in mouse SNI (sciatic nerve injury), promote the expression of neurotrophic factors and nerve growth factors, repair damaged nerve fibers, and promote the recovery of motor function and nerve function after SNI in mice. The present invention is the first to use allogeneic homologous dorsal root ganglion stem cells to treat sciatic nerve injury, providing a new idea for further research on peripheral nervous system regeneration.
[0013] Compared with the prior art, the present invention has the following beneficial effects: the present invention successfully uses the transcription factor Sox9 to induce primary satellite glial cells into neural stem cell-like cells after sciatic nerve injury. In this process, the present invention finds that DRG-SGCs may be transformed into "reactive DRG-SGCs" to respond to injury after injury, and knocking down Sox9 may cooperate with it to promote the reverse differentiation of injury-responsive DRG-SGCs. The induced cells meet the characteristics of neural stem cells: strong proliferation ability and directional differentiation potential. In addition, the neural stem cell-like cells can reduce the release of inflammatory factors in SNI mice, promote the expression of neurotrophic factors and nerve growth factors, repair damaged nerve fibers, and promote the recovery of motor function and nerve function after SNI in mice. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 The SNI model of C57BL / 6 mice and the extraction of DRG tissue; Figure legend: (a): The right sciatic nerve was clamped and cut off (the enlarged image in the upper left corner corresponds to the sciatic nerve in the black box), (b): DRG tissue was obtained under a dissecting microscope; Figure 2 For DRG-SGC immunofluorescence identification, Bar = 20 μm; Figure 3 This is the map of the pLV[shRNA]-EGFP / Puro-U6>mSox9[shRNA] expression vector; Figure 4 The plasmid maps of pHelper 1.0 vector (left) and pHelper 2.0 vector (right); Figure 5 qRT-PCR was used to detect Sox9 mRNA expression; Figure 6The subculture and immunofluorescence identification of sh-Sox9DRG-SGCs; Figure legend: (a): The morphological changes of DRG-SGCs before and after transfection were observed under an inverted microscope. The white box indicates the appearance of spheroid cells in SNI sh-Sox9DRG-SGCs culture, Bar=50μm; (b): Immunofluorescence identification of SNI sh-Sox9DRG-SGCs, Bar=100μm; Figure 7 The structure of SNIsh-Sox9DRG-SGCs after passage was observed by transmission electron microscopy; Figure legend: red arrows indicate cell nuclei; yellow arrows indicate nucleoli; green arrows indicate mitochondria; the black rectangles contain smooth endoplasmic reticulum and free ribosomes, Bar=5μm; Figure 8 Different volume fractions of FBS were used to induce differentiation of SNIsh-Sox9DRG-SGCs; Figure legend: (a): 1% FBS induced differentiation; (b): 5% FBS induced differentiation; (c): 10% FBS induced differentiation; Bar=100μm; Fig. 9 BrdU was used to detect the proliferation ability of SNIsh-Sox9DRG-SGCs injected with different cell amounts in DRG tissue for 1 week, n=3, *P<0.05, **P<0.01, Bar=100μm; Fig.10 BrdU was used to detect the proliferation ability of SNIsh-Sox9DRG-SGCs injected with different cell amounts in DRG tissues for 2 weeks, n=3, *P<0.05, Bar=100μm; Fig.11 The footprint recovery status of each group at 2 weeks and 4 weeks; Fig.12 The wet weight of gastrocnemius muscle in each group, n=10, **P<0.01; Fig.13 Masson staining of sciatic nerve fibers; Bar = 50 μm; Fig.14 qRT-PCR detection of mRNA expression of related factors after cell therapy; Figure legend: (a): expression of pro-inflammatory related factors IL-1β, IL-6, TNF-α mRNA in different groups at different time points, (b): expression of neurotrophic / growth related factors BDNF, NGF, GDNF mRNA in different groups at different time points, n=3, *P<0.05, **P<0.01; Fig.15 Western Blot was used to detect the expression of GAP43 protein in DRG tissue, n=3, **P<0.01. DETAILED DESCRIPTION
[0015] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments, but the present invention is not limited to the following technical solutions. In the following embodiments, miRNA sequencing was entrusted to Chongqing Life Source Technology Co., Ltd. for statistical analysis. Statistical analysis software GraphPad7.0 was used for statistical analysis and drawing of data. ImageJ (Ver1.8.0) software was used to count immunofluorescence positive cells and Western Blot grayscale values. The experimental data were statistically described using mean ± standard deviation, and ANOVA was used for multiple group comparison analysis. When the statistical result P<0.05 indicated that the difference was statistically significant.
[0016] Example 1 1. Establishment of Sciatic Nerve Injury Model Female C57BL / 6 mice 3-5 days after birth were intraperitoneally injected with 1% sodium pentobarbital solution (30 mg / kg). Forceps were used to cut 0.2 cm along the skin of the unilateral sciatic nerve trunk (the right leg in this experiment), and the muscle layer was directly separated with hemostatic forceps to expose the sciatic nerve stem cells, which were directly severed and the wound was sutured with surgical sutures. In the sham operation group, only the sciatic nerve was exposed. The groups were divided into sham operation group: Sham group; sciatic nerve injury group: SNI group.
[0017] 2. Primary Culture of DRG-SGCs 24 hours after modeling, mice in the Sham group and SNI group were injected with 1% sodium pentobarbital (30 mg / kg) intraperitoneally, fixed with ophthalmic forceps, and decapitated with scissors. Use clean scissors to cut the skin and ribs on the back of the mouse, remove the spine, peel off the muscles on the spine, and expose the spine. Clean the blood vessels and spinal cord under a dissecting microscope, use ophthalmic forceps to clamp out the DRG (dorsal root ganglion), separate the nerve fibers on the DRG, and peel off the capsule on the surface of the DRG. The treated DRG tissue was placed in a six-well plate prepared with polylysine, and the DRG-SGCs primary culture medium was added to the six-well plate. There were about 6-10 DRGs per well, and the plate was incubated at 37°C and 5% CO 2 Culture in an incubator.
[0018] DRG-SGCs primary culture medium components: DMEM / F12: 47 mL, B27: 1 mL, penicillin-streptomycin solution: 0.5 mL, L-glutamine: 0.5 mL, bovine serum albumin: 0.5 mL, neuregulin 1 (NRG-1β): 100 μL, dexamethasone: 152 μL, recombinant human insulin: 148 μL, triiodothyronine: 50 μL, thyroxine: 50 μL.
[0019] The results are as follows: C57BL / 6 mice were used to establish the SNI model, and the right sciatic nerve was clamped and cut ( Figure 1 a. Figure 1b), 24 hours later, the spine was dissected under a dissecting microscope, and L4-L6 DRG tissues on the left side (i.e., the side opposite to the injury) were removed with ophthalmic forceps. DRG-SGCs were cultured in primary culture and identified by immunofluorescence staining. At 3 days of culture, DRG-SGCs could be labeled with GFAP (glial fibrillary acidic protein) and GS (glutamine synthetase) under the microscope. Figure 2 GFAP and GS are markers of satellite glial cell activation and can characterize DRG-SGCs, indicating that the primary DRG-SGCs were successfully cultured.
[0020] 3. Construction of Sox9 knockdown stable DRG-SGCs The Sox9 knockdown DRG-SGCs were constructed using the lentiviral packaging system. According to the RNAi sequence design principles, three shRNA sequences (32681-1, 32681-2, and 32681-3) were designed (see Table 1).
[0021] Table 1 Sh-Sox9 target sequences
[0022] The construction method of the expression vector for knocking down Sox9 was completed by Shanghai GeneCare Gene Co., Ltd. The specific operation is as follows: The expression vector (pLV[shRNA]-EGFP / Puro series plasmid, GeneCare) and Sox9 interference fragment were double-digested with EcoRI and AgeI restriction endonucleases. The digestion system was 50 μL, including: 10×CutSmartBuffer 5 μL, purified plasmid DNA 2 μL, EcoRI 1 μL, AgeⅠ 1 μL, 41 μL ddH 2 O. Mix by pipetting and centrifugation, place at 37℃ for reaction, and recover the expression vector (plasmid) after electrophoresis. Connect the shRNA fragment to the linearized expression vector (plasmid) through T4 DNA ligase, connect at 16℃ for 1-3h, or connect overnight to obtain pLV[shRNA]-EGFP / Puro-U6>mSox9[shRNA]. Then introduce it into the target cells. It binds in the cell through the RNAi pathway to produce the effect of silencing Sox9.
[0023] The process of obtaining the shRNA is as follows: PCR amplification of the Sox9 CDS sequence, as shown in SEQ ID NO.4, the obtained double-stranded DNA is digested to obtain the shRNA Oligo fragment, and the shRNA fragment is connected to the plasmid to obtain pLV[shRNA]-EGFP / Puro-U6>mSox9[shRNA]( Figure 3 ).
[0024] Take 10 μL of pLV[shRNA]-EGFP / Puro-U6>mSox9[shRNA] and add it to 100 μL of competent cells. Tap the tube wall several times to mix well and place on ice for 30 minutes. Heat shock at 42℃ for 90 seconds and incubate in an ice water bath for 2 minutes. Add 500μL LB medium and place in a 37℃ shaker for 1 hour. Take an appropriate amount of bacterial liquid and evenly spread it in DMEM / F12 medium containing 0.1mg / mL ampicillin, and invert and culture in a constant temperature incubator for 12-16 hours. When colonies grow on the plate, pick an appropriate amount of colonies and place them in 3mL containing 100mg·L -1 In LB medium containing ampicillin, shake at 37°C overnight, and take appropriate amount of bacterial solution for PCR and agarose gel electrophoresis identification. The identification system is 20μL, including: 2×Taq Plus Master Mix 10μL, PCR upstream and downstream primers 0.4μL each, appropriate amount of bacterial solution, 9.2μL ddH 2 O. Blank control was ddH 2 O is a template used to detect whether there is contamination in the identification system.
[0025] Upstream primer F SEQ ID NO.6: CCTTCGACGTCAATGAGTTTG Downstream primer R SEQ ID NO.7: GCGACGTCATCTCCAACATTG The negative control used an empty vector without the target gene as a template (pLV[shRNA]-EGFP / Puro-U6) to prove that there was no false positive phenomenon during the amplification process. The identified positive clone transformants were inoculated in an appropriate amount of 100 mg·L -1 The cells were cultured in LB liquid medium containing ampicillin at 37°C for 12-16 hours, and an appropriate amount of bacterial solution was taken for sequencing. The plasmids of the positive bacteria that were successfully sequenced were extracted using a plasmid extraction kit and used in subsequent experiments.
[0026] Transfer the correctly sequenced bacterial solution into 10 mL of LB liquid medium containing the corresponding antibiotics and culture at 37°C overnight; Use Tiangen Endotoxin-free Plasmid Mini-Extraction Kit to extract plasmids. The detailed steps are as follows: 1. Collect the overnight cultured bacteria into a labeled 5 mL centrifuge tube and centrifuge at 12000 rpm for 2 min to collect the bacteria; 2. Discard the supernatant, add 250 μL of cell resuspension solution, and shake thoroughly to make the bacterial mass evenly suspended; 3. Add 250 μL of cell lysis buffer and 10 μL of proteinase K, invert 5-6 times, and gently mix; let stand for 1-2 minutes to allow the cells to lyse and clarify; 4. Add 350 μL of neutralizing solution, mix by inverting to completely precipitate the protein, and place in an ice bath for 5 minutes; 5. Centrifuge at 10000 rpm for 10 min, discard the protein, and collect the supernatant into another clean and sterile 1.5 mL EP tube; 6. Centrifuge at 12000rpm for 5min, prepare the labeled recovery column, transfer the supernatant to the recovery column, centrifuge at 12000rpm for 1min, and discard the waste liquid at the bottom; 7. Add 600 μL of pre-prepared rinse solution, centrifuge at 12000 rpm for 1 min, discard the lower layer of waste liquid, repeat once, centrifuge at 12000 rpm for 2 min to further remove the residual rinse solution; 8. Transfer the recovery column to a new 1.5mL EP tube in a clean bench, let it stand for 10-20 minutes, and dry naturally; 9. Add 95 μL Nuclease-Free Water to the recovery column, let stand for 2 min, centrifuge at 12000 rpm for 2 min, collect samples, number them, perform electrophoresis, determine the concentration, and conduct quality inspection. The expression vector for knocking down Sox9 is obtained, and the sequence of the entire vector is shown in SEQ ID NO.5.
[0027] The lentiviral packaging process is completed by GeneCare Genetics, and the specific process is as follows: 1. 24 h before transfection, trypsinize the 293T cells in the logarithmic growth phase and adjust the cell density to about 5×10 in a medium containing 10% serum. 6 Cells / 15mL, re-seeded in cell culture dishes, 37°C, 5% CO 2 Culture in an incubator. When the cell density reaches 70% to 80% after 24 hours, it can be used for transfection; 2. Change to serum-free medium 2 h before transfection; 3. Add the prepared DNA solutions (20 μg of pLV[shRNA]-EGFP / Puro-U6>mSox9[shRNA] expression vector, 15 μg of pHelper 1.0 vector plasmid, 10 μg of pHelper2.0 vector plasmid) to a sterilized centrifuge tube, mix well with the corresponding volume of GeneCare transfection reagent, adjust the total volume to 1 mL, and incubate at room temperature for 15 min. pLV[shRNA]-EGFP / Puro-U6: This is a vector for expressing shRNA, usually used for gene interference. It is provided by GeneCare Genetics. EGFP can be used as a reporter gene to facilitate the screening of successfully transfected cells.
[0028] pHelper 1.0 and pHelper 2.0 vectors: are auxiliary vectors required for lentiviral packaging, providing viral structural proteins and required transport factors. pHelper 1.0 and pHelper 2.0 vectors are from GeneCare Gene Corporation, and the vector maps are as follows: Figure 4 As shown in the left and right figures.
[0029] 4. Slowly add the mixture to the 293T cell culture medium, mix well, and incubate at 37°C and 5% CO 2 Culture in a cell culture incubator; Note: The addition process must be uniform and try not to blow up the cells.
[0030] 5. After 6 hours of culture, discard the culture medium containing the transfection mixture, add 10 mL of PBS solution to wash once, gently shake the culture dish to wash the remaining transfection mixture and then discard; 6. Slowly add 20 mL of cell culture medium containing 10% serum and incubate at 37°C and 5% CO 2 Continue culturing in the incubator for 48-72 hours.
[0031] 7. According to the cell status, collect the 293T cell supernatant 48h after transfection (transfection can be counted as 0h); 8. Centrifuge at 4000 g for 10 min at 4°C to remove cell debris; 9. Filter the supernatant with a 0.45 μm filter into a 40 mL ultracentrifuge tube; 10. Balance the samples separately, place the ultracentrifuge tubes with virus supernatant into the Beckman ultracentrifuge one by one, set the centrifugation parameters to 25000rpm, the centrifugation time to 2h, and the centrifugation temperature to 4℃; 11. After centrifugation, discard the supernatant, try to remove the liquid remaining on the tube wall, add virus preservation solution (can be replaced by PBS or cell culture medium), and gently blow repeatedly to resuspend; Note: There will be a certain degree of loss in virus recovery in this step, so try to avoid exposing the virus to room temperature for a long time.
[0032] 12. After fully dissolved, centrifuge at 10,000 rpm for 5 minutes and package the supernatant as required.
[0033] After the Sox9 knockdown vector was packaged by lentivirus, the virus solution was subjected to gradient transfection. The specific operation was as follows: 1 μL (MOI≈40) of the virus solution diluted 10 times (the virus stock solution (condensate) in the kit was diluted with PBS) was transferred into a 96-well plate containing 100 μL complete medium. According to the formula (MOI=virus titer (TU / mL) × virus volume (mL) / cell number, the cell MOI value was calculated to be about 40, and the subsequent cell experiments were performed at MOI≈40.
[0034] The lentiviral transfection of DRG-SGCs and the screening process were as follows: Grouping: Control group (blank group): no intervention, divided into surgical group (SNI) and sham operation group (Sham); Control group: empty group; sh-Sox9 group: stable Sham / SNI DRG-SGCs with Sox9 knockdown (knockdown group); 3 replicate wells were set up in each group.
[0035] The DRG-SGCs cells obtained above were spread on a 96-well plate, the old culture medium was discarded, the cells were washed (rinsed) with PBS, 1 mL of digestion solution (trypsin solution) was added, and digested at 37°C for 2 min. Observe the cells under a microscope: Observe the digested cells under an inverted microscope. The cytoplasm has shrunk and the cells are no longer connected into pieces. The cells are moderately digested. Immediately add 1 mL of complete culture medium to terminate the digestion. Make a suspension by blowing: Use a dropper to blow the digested cells into a cell suspension. Aspirate the cell suspension into a centrifuge tube: Aspirate the cell suspension into a 15 mL centrifuge tube, centrifuge at 1000 rpm for 5 min, and discard the supernatant. Add new culture medium: Add 2 mL of culture medium and use a pipette to gently blow the cells to make a cell suspension. Evenly spread the cell suspension in a 96-well plate, with a cell density of 1×10 5 Transfection is performed at around 70% to 80%.
[0036] The DRG-SGCs cell transfection and cell line construction process are as follows: According to the formula (MOI = virus titer (TU / mL) × virus volume (mL) / cell number, the optimal cell MOI value was calculated to be about 40. The DRG-SGCs cells were divided into a blank group, a control group (empty group) and a knockdown group. The blank group was not treated. The control group and the knockdown group were infected with lentivirus for 24 hours and the medium was changed. The culture was continued for 48 hours, and the resistance was selected in DMEM / F12 medium containing puromycin (5 μg / μL) and B27 (2% V / V) for 14 days. During this period, the cells were collected on the 3rd, 7th and 14th days. Under a fluorescence microscope, if the DRG-SGCs cells grew well and expressed green fluorescence, it indicated that the cell line was successfully constructed.
[0037] Immunofluorescence staining: cells were fixed by soaking in 4% paraformaldehyde solution for 20 min; rinsed with 0.01 mol / L PBS 3 times, 10 min each time. PBS was prepared with 5% goat serum for blocking at room temperature for 1 h; rinsed with 0.01 mol / L PBS 3 times, 10 min each time; added primary antibody (1:500) and placed in a wet box and incubated overnight in a 4°C refrigerator. The wet box was taken out and allowed to stand for 30 min, rinsed with PBST 3 times, 10 min each time; added fluorescent secondary antibody (1:500) and incubated at room temperature for 2 h (protected from light); rinsed with PBST 3 times, 10 min each time; added DAPI. Images were collected under an inverted fluorescence microscope.
[0038] Transmission electron microscopy: Collect cell pellets by centrifugation, remove the culture medium and add electron microscopy fixative at 4°C, resuspend and mix for 2-4 hours. Centrifuge, discard the supernatant and add 0.1M phosphate buffer PB (pH7.4), mix and rinse for 3 minutes, then centrifuge again, repeat washing 3 times. Prepare 1% agarose solution by heating and dissolving in advance, add it to the EP tube after cooling, and pick up the precipitate with tweezers before the agarose solidifies and suspend it in the agarose. Fix with 1% osmium acid prepared in 0.1M phosphate buffer PB (pH7.4) at room temperature in the dark for 2 hours. Rinse 3 times with 0.1M phosphate buffer PB (pH7.4), 15 minutes each time. Dehydrate at room temperature, and the tissue is sequentially placed in 30%-50%-70%-80%-95%-100%-100% alcohol, dehydrate for 20 minutes, and 100% acetone twice, 15 minutes each time. Infiltrate and embed with embedding medium, 37°C for 2-4 hours, oven overnight, and slice the next day. 2% uranyl acetate saturated alcohol solution was used for staining in the dark for 8 min; 70% alcohol was used for washing 3 times; ultrapure water was used for washing 3 times; 2.6% lead citrate solution was used for staining in the dark for 8 min; ultrapure water was used for washing 3 times, the sample was slightly dried with filter paper, and dried at room temperature overnight. The sample was observed under a transmission electron microscope and the images were collected for analysis.
[0039] Puromycin (5 μg / μL) resistance screening was performed for 14 days, during which cells were collected on the 3rd, 7th, and 14th days, and the Sox9 mRNA expression level was detected by qRT-PCR to evaluate the knockdown efficiency of the three sequences. The results showed that compared with the empty group and the blank control group, the Sox9 mRNA expression level in the knockdown group was downregulated, and the sh-Sox9-1 sequence was the best knockdown fragment (P<0.001) ( Figure 5 ).
[0040] In order to further observe the morphological changes of DRG-SGCs after knockdown of Sox9, Sham / SNIsh-Sox9DRG-SGCs were subcultured with 48 mL of DMEM / F12 medium (GIBCO), 1 mL of B27 supplement (GIBCO), and 1 mL of penicillin-streptomycin solution (HYCLONE), respectively, and observed under an inverted microscope and transmission electron microscope.
[0041] like Figure 6 As shown in a, only spheroid cells were observed in the SNIsh-Sox9DRG-SGCs group under an inverted microscope. Immunofluorescence staining was used to further detect the common stem cell markers Nestin and Sox2 in the SNIsh-Sox9DRG-SGCs after passage. Figure 6 As shown in b, SNIsh-Sox9DRG-SGCs can be co-stained with two markers. This result suggests that SNIsh-Sox9DRG-SGCs have neural stem cell-like characteristics.
[0042] Transmission electron microscopy was used to observe the structure of SNIsh-Sox9DRG-SGCs after passage. Figure 7 As shown in the figure, the nuclei of SNIsh-Sox9DRG-SGCs after passage are large and irregular, with multiple nucleoli, ribosomes and mitochondria in the cytoplasm, and other organelles are rare and simple in structure. This result indicates that SNIsh-Sox9DRG-SGCs after passage have not yet matured.
[0043] Nestin and Sox2 are recognized markers of neural stem cells. In order to identify the plasticity characteristics of SNIsh-Sox9DRG-SGCs, that is, whether they have stem cell morphological characteristics, immunofluorescence detection of the two markers was used for characterization. SNIsh-Sox9DRG-SGCs were induced and cultured with FBS at volume fractions of 1%, 5%, and 10%, respectively. The medium was changed every other day, and immunofluorescence labeling was performed after the cell morphology matured under the microscope.
[0044] 1% volume fraction FBS induction medium includes 50 mL DMEM / F12 and 0.5 mL FBS (fetal bovine serum); 5% volume fraction FBS induction medium includes 50 mL DMEM / F12 and 2.5 mL FBS; 10% volume fraction FBS induction medium includes 50 mL DMEM / F12 and 5 mL FBS; After culturing for 1 week, it was found that 1% FBS could induce SNIsh-Sox9DRG-SGCs to differentiate into MAP2-positive cells, and as the FBS volume fraction increased, the MAP2 fluorescence expression gradually decreased. 10% FBS could induce SNIsh-Sox9DRG-SGCs to differentiate into GS-positive cells, and as the FBS volume fraction decreased, the GS fluorescence expression gradually decreased ( Figure 8 ). This result suggests that SNIsh-Sox9DRG-SGCs have the ability to differentiate into different cells under FBS induction.
[0045] To further explore the survival rate and cell cycle of sh-Sox9DRG-SGCs, the CCK8 assay was first used to detect cell survival rate. Compared with the ShamDRG-SGCs group, the survival rate of the Shamsh-Sox9DRG-SGCs group was significantly decreased (P<0.01); at the same time, compared with the Shamsh-Sox9DRG-SGCs group, the cell survival rate of the SNIsh-Sox9DRG-SGCs group was increased (P<0.05). This result shows that after knocking down Sox9 in the SNIDRG-SGCs group, the cell survival rate increased and there was a regeneration phenomenon.
[0046] Flow cytometry was used to detect the cell cycle. The number of cells was calculated as 1×10 6 cells / mL were inoculated in a 24-well plate. Centrifuge at 800rpm for 5min, collect the cell pellet, discard the supernatant, wash twice with pre-cooled PBS, add pre-cooled 75% ethanol, and fix at 4℃ for 4h. Centrifuge at 800rpm for 5min, discard the supernatant, wash once with 3mL PBS, add 400μL ethidium bromide (PI, 50ug / mL) for cell staining, 100ulRNaseA (100ug / mL), and incubate at 4℃ in the dark for 60min. Detect by flow cytometry and analyze with ModFit software.
[0047] Flow cytometry results showed that the percentage of ShamDRG-SGCs in the G0G1 phase was 61.66%±0.75%, and the percentage of cells in the S phase was 19.55%±0.44%; the percentage of SNIDRG-SGCs in the G0G1 phase was 71.79%±0.36%, and the percentage of cells in the S phase was 12.5%±0.24%; the percentage of Shamsh-Sox9DRG-SGCs in the G0G1 phase was 75.45%±0.32%, and the percentage of cells in the S phase was 8.42%±0.3%; the percentage of SNIsh-Sox9DRG-SGCs in the G0G1 phase was 66.01%±0.36%, and the percentage of cells in the S phase was 13.47%±0.33%. Compared with the Shamsh-Sox9DRG-SGCs group and the SNI group, the percentage of cells in the G0G1 phase of SNIsh-Sox9DRG-SGCs decreased, while the percentage of cells in the S phase increased. This result indicates that knocking down Sox9 after SNI can enable DRG-SGCs to have an active cell cycle, which may be that DRG-SGCs are initiating the process of damage repair.
[0048] In addition, miRNA sequencing analysis was used to explore the miRNA expression profile in the plasticity phenomenon of sh-Sox9DRG-SGCs after SNI. Compared with Shamsh-Sox9DRG-SGCs, according to the screening conditions |log2foldchange|>0, Pvalue<0.05, padj<0.05, there were 16 differential miRNA expressions, of which 1 was upregulated and 15 were downregulated; by comparing with the miRBase (v22) database, 5 known miRNAs and 11 unknown miRNAs were obtained. The 5 known differential miRNAs were miRNA-381-3p, miRNA-5108, miRNA-5119, miRNA-5126, and miRNA-6240. Among them, combined with the research background and literature analysis, it was suggested that miRNA-381-3p was related to stem cell pluripotency and nerve injury repair. In order to analyze the differential miRNA more intuitively, the volcano map was used for visualization analysis; the cluster heat map was generated by Pearson correlation analysis, and the data obeyed the normal distribution after logarithmic transformation. KEGG results showed that differential miRNA target genes were mainly enriched in axon conduction, Wnt signaling pathway, tumor-related signaling pathway, and signaling pathway regulating stem cell pluripotency.
[0049] Application of the neural stem cell-like cells obtained in Example 2 Direct injection of allogeneic neural stem-like cells into the injured sciatic nerve of mice Female C57BL / 6 mice aged 2-3 months were intraperitoneally injected with 1% sodium pentobarbital solution (30 mg / kg). Forceps were used to cut 0.2 cm along the skin of the unilateral sciatic nerve trunk (all right legs in this experiment), and the muscle layer was directly separated with hemostatic forceps to expose the sciatic nerve trunk. The optimal cell amount was directly injected into the sciatic nerve trunk using a 5μL microsyringe. The optimal cell amount was explored by BrdU labeling method: 100 mg of BrdU powder was added to 10 mL of double distilled water. After it was fully dissolved, it was filtered and sterilized with a filter to prepare a 10 mg / mL solution, which was stored in a 4°C refrigerator away from light. It was then added to dorsal root ganglion stem cells with different counts and mixed, and injected at the site of sciatic nerve injury (50 mg / kg). The experiment was randomly divided into 3 groups, with 10 mice in each group: sham operation group (Sham group); surgery group injected with saline (SNI-Saline group) (negative control group); surgery group injected with dorsal root ganglion stem cells (SNIDRG-NSCs group).
[0050] Functional index evaluation Sciatic nerve function index (SNFI): Bain formula: SNFI = 109.5 (ETS-NTS) / NTS-38.3 (EPL-NPL) / NPL + 13.3 (EIT-NIT) / NIT-8.8. Sciatic nerve function index SNFI = 0 is normal, -100 is complete injury; 3 indicators of normal foot (N) and injured foot (E): A, PL (footprint length); B, TS (toe width); C, IT (intermediate toe width). SNFI = 0 is normal, -100 is complete injury.
[0051] Tarlov score: The modified Tarlov method was used to assess the motor function of the hind limbs of mice by the inclined board test.
[0052] Sciatic nerve trunk induced potential The induced potential amplitude on the sciatic nerve trunk was analyzed by BL-420F biological signal acquisition and analysis system, and the parameters were set as stimulation intensity 5V and stimulation frequency 10Hz.
[0053] Gastrocnemius wet weight The gastrocnemius muscle on the surgical side (the right side in this experiment) was taken and the wet weight of the muscle was measured using an electronic scale.
[0054] Masson staining Refer to the existing methods.
[0055] Immunohistochemistry Refer to the existing methods.
[0056] qRT-PCR Remove the culture medium, add 1xPBS solution to wash the cells, add 2mL0.25% trypsin, and shake gently to loosen the cells. Add 4mL fetal bovine serum to stop digestion, repeatedly blow and collect into a nuclease-free EP tube, centrifuge at 1100rpm for 5min, discard the supernatant, collect the precipitated cells, add 500μL RNA lysis solution, blow and mix with a pipette and transfer to a 1.5mL nuclease-free EP tube. Add 500μL RNA diluent, let stand at room temperature for 3-5min, centrifuge at 12000rpm for 5min, aspirate the supernatant, add 0.5 times the volume of supernatant anhydrous ethanol, blow and beat 20-25 times with a pipette. Transfer the mixture to a centrifugal column, centrifuge at 12000rpm for 1min, discard the filtrate, add 50μL DNase 1 incubation solution, and let stand at room temperature for 15min. Add 600μL RNA washing solution, centrifuge at 12000rpm for 1min, and discard the filtrate. Repeat once. Transfer the centrifugal column to the elution tube, add 200 μL of nuclease-free water, stand at room temperature for 2 minutes, centrifuge at 12000 rpm for 1 minute, and collect the extracted RNA. Take RNA as a template, prepare the cDNA reaction system on ice, mix gently and place it in the PCR amplification instrument. Prepare the qRT-PCR reaction system, obtain the melting curve, CT value, and analyze the data. The relevant primer sequences are shown in Table 2.
[0057] Table 2 Primer sequences
[0058] Western Blot Extraction of total protein from tissues Place a small amount of chopped tissue pieces in a 2mL EP tube, add 200μL detergent lysis solution (containing 2μLPMSF, 2μL phosphatase inhibitor) to each tube for lysis, and place in an automatic homogenizer for homogenization. After homogenization, place the EP tube on ice for 30 minutes to fully lyse. After 30 minutes of lysis, use a pipette to transfer the lysate to a 1.5mL centrifuge tube, then centrifuge at 12000rpm for 5 minutes at 4℃, take the supernatant and divide it into 0.5mL centrifuge tubes and store at -20℃.
[0059] Determination of protein concentration Dilute the protein samples appropriately (take 1 μL of each sample and mix with 19 μL of PBS for dilution, that is, the test sample is diluted 20 times. Dilute the BSA standard to make standard proteins with protein concentrations of 1, 0.8, 0.6, 0.4, and 0.2 (unit: mg / mL). Add the protein samples diluted with PBS and the diluted standard proteins to a 96-well plate, respectively. Set up 2 parallel wells for each standard sample and 3 parallel wells for the sample to be tested, and add 20 μL to each well. The two parallel wells with PBS are blank controls. Mix solution A and solution B in the BCA kit at a ratio of 50:1, add the mixed solution to a 96-well plate, and add 200 μL to each well. Be careful not to generate bubbles to avoid affecting the reaction. Incubate at 7°C in the dark for 15 minutes. Measure the OD value with an enzyme marker. Calculate the linear regression equation based on the standard protein concentration and the corresponding OD value. Calculate the sample protein concentration using the regression equation based on the OD value of the protein sample.
[0060] Protein denaturation Mix the extracted protein supernatant with 5× protein loading buffer (volume ratio of 4:1) and place in boiling water for 10 minutes. Check whether the sample is transparent and then use a pipette to aspirate to see if it is viscous. If it is not transparent or viscous, the boiling time needs to be extended. After denaturation, cool to room temperature and store at -20℃.
[0061] Preparation of electrophoresis gel After cleaning and drying the glass plate, fix it on the gel making machine and start preparing the separation gel. Pour the separation gel into the gap of the glass plate to an appropriate height and cover the separation gel with anhydrous ethanol until the gel is completely polymerized. Pour out the anhydrous ethanol, rinse gently with double distilled water and dry with filter paper, then add concentrated gel to an appropriate height and insert the comb teeth. Remove the comb teeth after the concentrated gel is completely polymerized.
[0062] Electrophoretic separation Fix the prepared gel to the electrophoresis tank and pour the electrophoresis solution into the reservoir. Use a pipette to add the prepared protein sample and MAKER to the loading well, with a total protein amount of 40μg for each sample. After adding the sample, first run the electrophoresis at a constant voltage of 80V until the bromophenol blue indicator forms a line at the junction of the concentrated gel and the separation gel, then change to a constant voltage of 120V until the bromophenol blue reaches the bottom of the gel.
[0063] Electrotransfer Take out the gel and cut the target band according to the marker, rinse with distilled water, cut the PVDF membrane and filter paper of the same size as the PAGE gel, soak the PVDF membrane in methanol for a few seconds and then soak it in the electrotransfer buffer together with the filter paper. Place the black plate-fiber pad-filter paper-gel-PVDF membrane-filter paper-fiber pad-white plate in order, clamp the plate and put it into the transfer instrument, with one side of the black plate against the black negative electrode. Fill the transfer tank with electrotransfer solution and start the transfer.
[0064] Blocking and immunoblotting Soak the PVDF membrane in TBST (blocking solution) containing 5% skim milk powder and block it on a shaker at room temperature for 2 hours. Dilute the corresponding primary antibody (1:1000) with the blocking solution, soak the PVDF membrane in the primary antibody incubation solution, and incubate it at 4°C overnight. Wash the PVDF membrane with TBST for 5 times, 5 minutes each time. During the membrane washing process, pay attention to whether the membrane sticks to the wall of the dish or whether the membrane overlaps. Dilute the corresponding HRP-labeled secondary antibody with TBST, soak the PVDF membrane in the secondary antibody incubation solution, and incubate it on a shaker at room temperature for 2 hours. Wash the PVDF membrane with TBST for 5 times, 5 minutes each time. Develop with developer solution, fix with fixer solution, rinse the film; dry the film, and scan the film.
[0065] Exploring the optimal injection dose of dorsal root ganglion stem cells Different counts of dorsal root ganglion stem cell single cell suspensions mixed with BrdU were directly injected into the SNI of mice, and the proliferation capacity of different counts of dorsal root ganglion stem cells in DRG tissue was detected by immunofluorescence at 1 week and 2 weeks after injection. Fig. 9 As shown, 1×10 6 pcs, 1×10 7 pcs, 1×10 8 After 1 week, the results of immunofluorescence staining showed that the positive rates of cells in DRG tissue were 11.85%±0.41%, 18.27%±0.1%, and 22.1%±0.57%, respectively. Therefore, injection of 1×10 8 The positive cell rate in DRG tissue was higher than that in the case of injection of 1×10 6 , 1×10 7 The number of cells was higher (P<0.05, P<0.01). Fig.10 As shown, 1×10 6 pcs, 1×10 7 pcs, 1×10 8 After 2 weeks, the positive rates of DRG cells were 13.99%±0.36%, 18.65%±0.33%, and 17.82%±0.36%, respectively. 8 The positive cell rate in DRG tissue was higher than that in the case of injection of 1×10 6 The number of cells was high (P<0.05). This result showed that 1×10 8 The dorsal root ganglion stem cells with a cell number of about 1×10 8 The optimal dose was 10 μL of cells.
[0066] Sciatic nerve function index (SNFI) evaluation After the injection of dorsal root ganglion stem cells (neural stem cells obtained in Example 1), the SNFI values were compared at five time points: 1w, 2w, 4w, 8w, and 12w. The PL (footprint length), TS (toe width), and IT (intermediate toe width) were measured by footprints, and the SNFI values were substituted into the formula to obtain the SNFI values. The results showed that after SNI, the SNFI values of each group were <0, indicating that the injury model was successfully established. The SNFI values of the SNIDRG-NSCs group showed an upward trend compared with the SNI-Saline group (Table 3).
[0067] At 2 weeks and 4 weeks, the footprints of the SNI-Saline group showed that the toes of the mice could not be fully opened, while the footprints of the SNIDRG-NSCs group showed that the toes of the mice were opened and gradually recovered to the walking state ( Fig.11 ).
[0068] Table 3 SNFI values at different time points in different groups (n=10, )
[0069] Tarlov score The Tarlov score of the injured (right) lower limb of mice was evaluated by the inclined board test (Table 4). The neurological function of the SNIDRG-NSCs group began to recover at 2 weeks compared with the SNI-Saline group, and the neurological function was completely restored at 8 weeks. This result suggests that SNIDRG-NSCs can promote the recovery of motor function in mice after SNI.
[0070] Table 4 Tarlov neurological function score (n=10)
[0071] Table Notes: 0 points: Complete paralysis of lower limbs. 1 point: Perceptible movement of lower limb joints. 2 points: The lower limbs can move freely, but cannot stand. 3 points: Can stand but cannot walk. 4 points: The motor function of the lower limbs is fully recovered and can walk normally.
[0072] Comparison of potential amplitudes of sciatic nerve trunks The potential amplitude of the sciatic nerve trunk was measured by transcranial electrical stimulation using a biological signal acquisition instrument. The collected data analysis showed that after SNI, the potential amplitude of the sciatic nerve trunk gradually increased with the extension of treatment and recovery time. From 1w to 4w, the potential amplitude of the sciatic nerve trunk in the SNIDRG-NSCs group was higher than that in the SNI-Saline group (P<0.05). This result suggests that SNIDRG-NSCs can promote the recovery of neurological function after SNI (sciatic nerve injury) in mice (Table 5).
[0073] Table 5 Sciatic nerve trunk evoked potentials (n=10, )
[0074] Table Notes: a indicates that the difference between SNIDRG-NSCs group and SNI-Saline group was statistically significant. a P<0.05.
[0075] Comparison of gastrocnemius muscle wet weight The gastrocnemius muscle on the injured side (right side) of SNI mice was weighed, and the statistical results showed that the wet weight of the gastrocnemius muscle in the SNIDRG-NSCs group was higher than that in the SNI-Saline group at 1 and 4 weeks after injury (P<0.01). This result suggests that SNIDRG-NSCs has a repairing effect on SNI in mice ( Fig.12 ).
[0076] Masson staining of sciatic nerve fibers Masson staining was used to observe the morphological changes of sciatic nerve fibers in the Sham group, SNI-Saline group, and SNIDRG-NSCs group. Fig.13 As shown, the nerve fibers in the Sham group were blue-purple, arranged regularly and densely; the nerve fibers in the SNI-Saline group were disordered, missing and irregular; and some nerve fibers in the SNIDRG-NSCs group were evenly distributed. This result further shows that SNIDRG-NSCs can repair damaged nerve fibers.
[0077] qRT-PCR detection of inflammatory factors and neurotrophic factors like Fig.14 As shown in a, qRT-PCR detected that the mRNA expression of pro-inflammatory factors IL-6 and IL-1β in the SNIDRG-NSCs group was downregulated compared with the SNI-Saline group at the 1-week time point (P<0.05, P<0.01); the mRNA expression of TNF-α, IL-6, and IL-1β in the SNIDRG-NSCs group was downregulated compared with the SNI-Saline group at the 2-week time point (P<0.05, P<0.01); the mRNA expression of TNF-α and IL-6 in the SNIDRG-NSCs group was downregulated compared with the SNI-Saline group at the 4-week time point (P<0.01). Fig.14As shown in b, the mRNA expression of GDNF and NGF in the SNIDRG-NSCs group was upregulated compared with that in the SNI-Saline group at 1 week (P<0.05, P<0.01); the mRNA expression of NGF in the SNIDRG-NSCs group was upregulated compared with that in the SNI-Saline group at 2 weeks (P<0.01); the mRNA expression of BDNF and NGF in the SNIDRG-NSCs group was upregulated compared with that in the SNI-Saline group at 4 weeks (P<0.05, P<0.01). The above results indicate that the injection of SNIDRG-NSCs reduces the release of inflammatory factors in SNI mice and promotes the expression of neurotrophic factors and nerve growth factors.
[0078] Western Blot detection of GAP43 expression like Fig.15 As shown in the figure, after SNIDRG-NSCs treatment, the expression of GAP43 protein in the SNIDRG-NSCs group was upregulated compared with the SNI-Saline group at 2 weeks (P<0.01). This result suggests that SNIDRG-NSCs treatment of mice with SNI can transiently promote the expression of GAP43.
[0079] In summary, neural stem cell-like cells can reduce the release of inflammatory factors in SNI mice, promote the expression of neurotrophic factors and nerve growth factors, repair damaged nerve fibers, and promote the recovery of motor function and nerve function after SNI in mice. They can be used to prepare drugs for the treatment of sciatic nerve injury.
Claims
1. A method for inducing satellite glial cells to reversely differentiate into neural stem cell-like cells, characterized in that: Dorsal root ganglia after sciatic nerve injury were obtained and placed in primary culture medium for culture to obtain dorsal root ganglion satellite glial cells, the constructed Sox9 knockdown expression vector was packaged by lentivirus and then transfected into dorsal root ganglion satellite glial cells, and DMEM / F12 culture medium containing puromycin was used to screen dorsal root ganglion satellite glial cells with stable expression; then the dorsal root ganglion satellite glial cells were cultured successively with improved DMEM / F12 culture medium and FBS induction culture medium to obtain neural stem cell-like cells; The process of constructing a shRNA expression vector for knocking down Sox9 is as follows: inserting the shRNA sequence into the plasmid, and then transfecting the expression vector into cells, wherein the target sequence of the shRNA is shown in SEQ ID NO.1, and the sequence of the expression vector is shown in SEQ ID NO.5; and the expression vector is packaged by lentivirus.
2. The method for inducing satellite glial cells to reversely differentiate into neural stem cell-like cells according to claim 1, characterized in that: The construction process of the expression vector for knocking down Sox9 is as follows: The plasmid and Sox9 interference fragment were double-digested with EcoR I and Age I restriction endonucleases, and the linear plasmid was recovered after electrophoresis; the Sox9 CDS sequence was amplified by PCR, and the obtained double-stranded DNA was digested to obtain the shRNA Oligo fragment, and the shRNA fragment was connected with the plasmid to obtain pLV[shRNA]-EGFP / Puro-U6>mSox9[shRNA]; Add pLV[shRNA]-EGFP / Puro-U6>mSox9[shRNA] to competent cells, flick the tube wall several times to mix, place on ice for 20-40 minutes, heat shock at 41-43℃ for 80-100 seconds, incubate in ice water bath for 1.5-2.5 minutes, add LB medium, place on a 37℃ shaker for 0.8-1.2 hours; take the bacterial solution and evenly spread it in DMEM / F12 medium containing 0.09-0.11mg / ml ampicillin, and invert and culture in a constant temperature incubator for 12-16 hours; when colonies grow on the plate, pick an appropriate amount of colonies and place them in a medium containing 90-110mg·L -1 In LB medium containing ampicillin, shake at 36.8-37.2℃ overnight, and take an appropriate amount of bacterial solution for PCR and agarose gel electrophoresis identification; The identified positive clone transformants were inoculated into a medium containing 90-110 mg·L -1 The cells were cultured in ampicillin-containing LB liquid medium at 36.8-37.2°C for 12-16 hours, and an appropriate amount of bacterial solution was taken for sequencing. The plasmids of the positive bacteria with successful sequencing were extracted using a plasmid extraction kit, and then lentiviral packaging was performed.
3. The method for inducing satellite glial cells to reversely differentiate into neural stem cell-like cells according to claim 1, characterized in that: The improved DMEM / F12 medium is a DMEM / F12 medium added with 1.5-2.5% (V / V) B27 and 1.5-2.5% (V / V) penicillin-streptomycin solution.
4. The method for inducing satellite glial cells to reversely differentiate into neural stem cell-like cells according to claim 3, characterized in that: The composition of the FBS induction medium is as follows: 0.5-5 mL of FBS is added to 50 mL of improved DMEM / F12 medium.
5. Neural stem cell-like cells obtained according to the method for inducing reverse differentiation of satellite glial cells into neural stem cell-like cells according to any one of claims 1 to 4.
6. Use of the neural stem cell-like cells according to claim 5 in the preparation of a drug for repairing sciatic nerve damage.
Citation Information
Patent Citations
Method for inducing transdifferentiation of satellite glial cells to neurons
CN110982788A
ShRNA interference sequence of human hWAPL gene as well as construction and application of shRNA interference sequence
CN118516350A
Method for Reprogramming Cell
US20230416676A1
